What was studied?
This single-center phase 1b study randomized 96 adults with overweight or obesity. Both comparison groups received semaglutide, with either cagrilintide or matched placebo added.
What did the researchers report?
The investigators examined adverse events and drug exposure. Exploratory weight findings favored some combination groups; gastrointestinal events featured prominently in the safety observations.
What are the limits?
This was a small, early study with exploratory efficacy outcomes. Its comparator was not an untreated group. It is not a recipe for combining products, and larger trials are needed to assess broader effects.
Original editorial summary by Sulan Peptide. Based on the source abstract; consult the full paper for methods, analyses, funding and disclosures.